Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma.

Davidsson, Elsa; Murgia, Nicola; Ortiz-Villalón, Cristian; Wiklundh, Emil; Sköld, Magnus; Kölbeck, Karl Gustav; Ferrara, Giovanni

Davidsson, Elsa; Murgia, Nicola; Ortiz-Villalón, Cristian; Wiklundh, Emil; Sköld, Magnus; Kölbeck, Karl Gustav; Ferrara, Giovanni.

Afiliación

Davidsson E; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
Murgia N; Section of Occupational Medicine, Respiratory Diseases and Toxicology, University of Perugia, Perugia, Italy.
Ortiz-Villalón C; Department of Pathology, Karolinska University Hospital, Stockholm, Sweden.
Wiklundh E; Oncology-Pathology Unit, Karolinska Institutet, Stockholm, Sweden.
Sköld M; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
Kölbeck KG; Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, 17176 Sweden.
Ferrara G; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.

Multidiscip Respir Med ; 12: 16, 2017.

Article en En | MEDLINE | ID: mdl-28560038

Palabras clave

Mutation; Non-small cell lung cancer; Precision medicine; Thromboembolism; Tyrosine kinase inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Multidiscip Respir Med Año: 2017 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Italia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google